SCHEMBL2887724

SCHEMBL2887724

[c]1ccc(OC2CCCC2)c(OC2CCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.37
PDE4A P27815 5/20 0.35
MCHR1 Q99705 2/20 0.35
CYP19A1 P11511 4/20 0.33
RECQL P46063 1/20 0.33
PDE4B Q07343 6/20 0.33
PDE4C Q08493 4/20 0.33
PDE4D Q08499 4/20 0.33
MEN1 O00255 1/20 0.32
PTGES O14684 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
PTGS1 P23219 1/20 0.32
CYP2C19 P33261 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17710554 0.96 CSNK2A1 (0.33) CSNK2A1PDE4AMCHR1CYP19A1RECQL
SCHEMBL315053 0.89 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2887418 0.89 PDE4A (0.44) PDE4ARECQLPDE4BPDE4CPDE4D
SCHEMBL8492806 0.88 PDE4A (0.43) PDE4ARECQLPDE4BPDE4CPDE4D
SCHEMBL28757119 0.86 PDE4D (0.44) PDE4APDE4BPDE4CPDE4D
SCHEMBL2885764 0.85 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2882676 0.85 SLC6A4 (0.40) CSNK2A1PDE4AMCHR1RECQLPDE4B
SCHEMBL2882597 0.85 SLC6A4 (0.43) CSNK2A1PDE4AMCHR1PDE4BPDE4C
SCHEMBL28476259 0.84 SLC6A2 (0.46) PDE4APDE4BTSHR
SCHEMBL14742168 0.83 CSNK2A1 (0.47) CSNK2A1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202880-B2 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors NYCOMED GMBH (DE) 2012-06-19 US disclosed
US-7776893-B2 Use of PDE4 inhibitors for the treatment of diabetes mellitus NYCOMED GMBH (DE) 2010-08-17 US disclosed
US-7632844-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2009-12-15 US disclosed
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors NYCOMED GMBH (DE) 2009-07-02 US disclosed
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH 2008-12-25 US disclosed
US-7423046-B2 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors NYCOMED GMBH (DE) 2008-09-09 US disclosed
US-7329676-B2 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors NYCOMED GMBH (DE) 2008-02-12 US disclosed
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors ALTANA PHARMA AG (DE) 2007-11-08 US disclosed
EP-1536798-B1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2007-02-07 EP disclosed
EP-1539164-B1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2006-12-20 EP disclosed
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors ALANA PHARMA AG (DE) 2005-10-27 US disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2005023253-A1 USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS ALTANA PHARMA AG (DE) 2005-03-17 WO disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
US-6476025-B1 Phenylphennanthridines with PDE-IV inhibiting activity ALTANA PHARMA AG (DE) 2002-11-05 US disclosed
EP-1147089-A1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-10-24 EP disclosed
WO-2000042020-A1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259909-A1 Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors PDE4A, PDE4B, PDE4D CSNK2A1 2324/4885PDE4A 1/4885MCHR1 3525/4885
US-20080319067-A1 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors PDE4A, PDE4B, PDE3A CSNK2A1 1245/4885PDE4A 1/4885MCHR1 1866/4885
US-20050239818-A1 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors PDE4A, PDE4B, PDE3A CSNK2A1 1533/4885PDE4A 1/4885MCHR1 1930/4885
US-20090170892-A1 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors PDE4A, PDE4B, PDE3A CSNK2A1 1565/4885PDE4A 1/4885MCHR1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.